Trial Profile
A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Prednisolone acetate
- Indications Anterior uveitis
- Focus Registrational; Therapeutic Use
- Sponsors EyeGate Pharma; Kiora Pharmaceuticals
- 04 Sep 2018 According to EyeGate Pharma media release, company announced top-line results from this trial.
- 04 Sep 2018 Results published in the EyeGate Pharma Media Release
- 04 May 2015 The US FDA provided guidance that if a confirmatory phase III trial of EGP-437 in anterior uveitis ((see trial profile 700255415) meets non-inferiority criteria, data from that trial along with data from this trial will be sufficient to support a New Drug Application (NDA) filing, according to an EyeGate Pharma media release.